PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.

Abstract:

AIM:This meta-analysis aims at assessing the correlation of PD-L1 levels and response PD-1/PD-L1 inhibitors in advanced malignant melanoma. METHODS:Eligible studies included those evaluating PD-1/PD-L1 inhibitors in advanced melanoma and correlating the outcomes to PD-L1 levels. RESULTS:After preclusion of ineligible studies, 11 studies were included. For PD-L1 >1% patients versus PD-L1 <1% patients treated with PD-1/PD-L1 targeted agents, the OR of ORR was 2.81 (95% CI: 1.64-4.82; p = 0.0002); while for PD-L1 >5% patients versus PD-L1 <5% patients, it was 2.22 (95% CI: 1.71-2.87; p < 0.00001). CONCLUSION:The current analysis indicates the value of PD-L1 positivity in predicting higher response from PD-1/PD-L1 agents. This molecular predictor - together with other predictors - may help further individualize treatment options for metastatic melanoma patients.

journal_name

Immunotherapy

journal_title

Immunotherapy

authors

Abdel-Rahman O

doi

10.2217/imt-2016-0025

subject

Has Abstract

pub_date

2016-09-01 00:00:00

pages

1081-9

issue

9

eissn

1750-743X

issn

1750-7448

journal_volume

8

pub_type

杂志文章,meta分析
  • The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.

    abstract::After the first wave of the tsunami of immune checkpoint inhibitors, 2016 was marked by the second wave, revealed by numerous US FDA approvals, publications and abstracts in relation with these drugs in different cancers and settings. First, we reported all new indications of anti-CTLA4, anti-programmed cell death pro...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0029

    authors: Kourie HR,Awada G,Awada A

    更新日期:2017-06-01 00:00:00

  • Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution.

    abstract::Rituximab is a chimeric monoclonal antibody used to treat hematologic and autoimmune diseases by depleting CD20-expressing B cells. Patients may develop hypogammaglobulinemia following treatment, with some demonstrating failure of B-cell recovery. The true frequency of hypogammaglobulinemia and/or impaired B-cell reco...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0178

    authors: Sacco KA,Abraham RS

    更新日期:2018-06-01 00:00:00

  • JAK2 inhibition in murine systemic lupus erythematosus.

    abstract::Systemic lupus erythematosus is a systemic autoimmune disease characterized by the presence of myriad autoantibodies, some with pathogenic potential, and diverse clinical manifestations. Involvement of the kidney is a major cause of morbidity and mortality in human lupus patients and in murine models of the disease. I...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.20

    authors: Tagoe C,Putterman C

    更新日期:2012-04-01 00:00:00

  • Adjuvant immunotherapies as a novel approach to bacterial infections.

    abstract::The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, ur...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.13.17

    authors: Helbig ET,Opitz B,Sander LE

    更新日期:2013-04-01 00:00:00

  • Heat-shock proteins in diagnosis and treatment: an overview of different biochemical and immunological functions.

    abstract::Heat-shock proteins (HSPs) have been involved in different functions including chaperone activity, protein folding, apoptosis, autophagy and immunity. The HSP families have powerful effects on the stimulation of innate immune responses through Toll-like receptors and scavenger receptors. Moreover, HSP-mediated phagocy...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2018-0105

    authors: Milani A,Basirnejad M,Bolhassani A

    更新日期:2019-02-01 00:00:00

  • Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

    abstract::HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 respo...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2016-0052

    authors: De La Cruz LM,Nocera NF,Czerniecki BJ

    更新日期:2016-10-01 00:00:00

  • Cancer CARtography: charting out a new approach to cancer immunotherapy.

    abstract::Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Recently, chimeric antigen receptor (CAR) T-cell immunotherapy has entered clinical trials in patients with relapsed or refr...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.14.44

    authors: Patel JM,Dale GA,Vartabedian VF,Dey P,Selvaraj P

    更新日期:2014-01-01 00:00:00

  • Modulatory effects of bortezomib on host immune cell functions.

    abstract::Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growt...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.66

    authors: Pellom ST Jr,Dudimah DF,Thounaojam MC,Sayers TJ,Shanker A

    更新日期:2015-01-01 00:00:00

  • Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy?

    abstract::Sarcoidois is an inflammatory disease of unknown origin characterized by the abnormal accumulation of noncaseating granulomas at sites of disease activity in multiple organs throughout the body with a predilection for the lungs. Because the exact trigger that leads to disease activity is still under investigation, cur...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.103

    authors: Celada LJ,Drake WP

    更新日期:2015-01-01 00:00:00

  • Dendritic cell vaccines targeting survivin in head and neck cancer.

    abstract::Evaluation of: Turksma AW, Bontkes HJ, Ruizendaal JJ et al. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J. Transl. Med. 11, 152-165 (2013). Survivin has been identified to be an inhibitor of apoptosis and is highly expressed in many cancers. A number o...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.120

    authors: Lee WT

    更新日期:2013-11-01 00:00:00

  • A novel microcrystalline tyrosine-adsorbed, mite-allergoid subcutaneous immunotherapy: 1-year follow-up report.

    abstract:AIM:A 1-year follow-up study comparing the safety and tolerability of the dosing schedules, satisfaction and effectiveness of a novel microcrystalline tyrosine-adsorbed mite (Dermatophagoides pteronyssinus)-allergoid subcutaneous immunotherapy (Acarovac Plus™) in 30 adult patients (18-65 years) with allergic rhinitis a...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2016-0068

    authors: Roger A,Depreux N,Jurgens Y,Serra AT,Heath MD,Garcia G,Skinner MA

    更新日期:2016-10-01 00:00:00

  • Interview: Investigating immunomodulators among the Actinomycetales. Interview by Hannah Wilson.

    abstract::John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...

    journal_title:Immunotherapy

    pub_type: 面试,新闻

    doi:10.2217/imt.13.27

    authors: Stanford JL

    更新日期:2013-05-01 00:00:00

  • EBV and nasopharyngeal carcinoma: a target for cellular therapies.

    abstract::Evaluation of: Li F, Song D, Lu Y, Zhu H, Chen Z, He X. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy. J. Immunother. 36(3), 208-214 (2013). The association of EBV with a number of human maligna...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.68

    authors: Smith C

    更新日期:2013-08-01 00:00:00

  • Genetic modification of natural killer cells for adoptive cellular immunotherapy.

    abstract::Immunotherapy of cancer is a rapidly developing field; one such development is the manipulation and use of natural killer (NK) cells. These cells with 'killer instincts' are an attractive cell to utilize, as they are directly reactive toward tumor and could potentially activate the endogenous adaptive immune system. T...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.09.36

    authors: Pegram HJ,Kershaw MH,Darcy PK

    更新日期:2009-07-01 00:00:00

  • Mechanisms of immunomodulation in human glioblastoma.

    abstract::Glioblastoma multiforme (GBM), WHO grade IV astrocytoma, is the most dramatic primary brain cancer with a very poor prognosis due to inevitable disease recurrence. Less than 10% of GBM patients are still alive 5 years after diagnosis despite a multimodal treatment with surgical resection of the tumor, radiation therap...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.39

    authors: Avril T,Vauleon E,Tanguy-Royer S,Mosser J,Quillien V

    更新日期:2011-04-01 00:00:00

  • Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation.

    abstract::Alemtuzumab (Campath®, Genzyme Corporation, MA, USA) is a potent monoclonal antilymphocyte, anti-CD52 antibody. Since the 1980s, alemtuzumab has been used extensively in organ transplantation as an induction agent - also with the aim of avoiding or reducing maintenance immunosuppression. We herein review the literatur...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.68

    authors: Weissenbacher A,Boesmueller C,Brandacher G,Oellinger R,Pratschke J,Schneeberger S

    更新日期:2010-11-01 00:00:00

  • The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer.

    abstract::There has been a surge in the use of immunotherapy for genitourinary malignancies. Immunotherapy is an established treatment for metastatic renal cell carcinoma and nonmuscle invasive bladder cancer, but its potential for treating prostate cancer (PCa) remains under investigation. Despite reported survival benefits, n...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0051

    authors: Sathianathen NJ,Krishna S,Konety BR,Griffith TS

    更新日期:2017-09-01 00:00:00

  • Efficacy of a 3-year course of sublingual immunotherapy for mite-induced allergic rhinitis with a 3-year follow-up.

    abstract::Aim: To evaluate the long-term efficacy of sublingual immunotherapy (SLIT) in treating mite-sensitized allergic rhinitis (AR). Materials & methods: 150 AR children were randomly divided into SLIT and pharmacotherapy (PT) groups, receiving a 3-year course of SLIT along with PT or PT only. Results: The symptom and medic...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0006

    authors: Chen WB,Shen XF,Li Q,Zhou WC,Cheng L

    更新日期:2020-08-01 00:00:00

  • Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.

    abstract::Rheumatoid arthritis (RA) is a chronic inflammatory disease in which persistent inflammation of synovial tissue results in a progressive functional decline of the joint and premature mortality. TNF inhibitors were the first biological disease-modifying antirheumatic drugs (DMARDs) used to treat RA. Since then, new bio...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.26

    authors: García-Hernández MH,González-Amaro R,Portales-Pérez DP

    更新日期:2014-01-01 00:00:00

  • Phacilitate Barcelona active immunotherapeutics forum. 11-13 May 2011, Barcelona, Spain.

    abstract::The era of active immunotherapy has now been successfully ushered into the clinical realm of advanced prostate cancer. The successful clinical trial development and US FDA approval of sipuleucel-T (Provenge®) has revamped the therapeutic paradigm for advanced prostate cancer. Nonetheless, physician and patient educati...

    journal_title:Immunotherapy

    pub_type: 总体

    doi:10.2217/imt.11.90

    authors: Shore ND

    更新日期:2011-08-01 00:00:00

  • Modulation of antitumor immunity with histone deacetylase inhibitors.

    abstract::Histone deacetylase inhibitors possess a broad array of antitumor activities; however, their net impact on the evolving antitumor immune response is highly dependent on the inhibitors used and the histone deacetylases they target. Herein, we sequentially focus on each stage of the antitumor immune response - from dend...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0134

    authors: McCaw TR,Randall TD,Forero A,Buchsbaum DJ

    更新日期:2017-12-01 00:00:00

  • Adoptive T-cell transfer in melanoma.

    abstract::Immunotherapy holds a highly promising treatment approach for metastatic melanoma patients. Adoptive cell transfer (ACT) involves the ex vivo expansion of autologous antitumor reactive lymphocytes and their reinfusion into lymphodepleted patients, accompanied by IL-2 administration. ACT with tumor-infiltrating T lymph...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.12.143

    authors: Itzhaki O,Levy D,Zikich D,Treves AJ,Markel G,Schachter J,Besser MJ

    更新日期:2013-01-01 00:00:00

  • Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea.

    abstract:AIM:Previous studies showed that some patients after the treatment of anti-programmed cell death protein-1 (anti-PD-1) antibodies experienced immune-related diarrhea. In this study, we aim to explore the association between intestinal microbiota and immune-related diarrhea. METHODS:We obtained the fecal samples of 26 ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2018-0144

    authors: Liu T,Xiong Q,Li L,Hu Y

    更新日期:2019-04-01 00:00:00

  • PLAC1 immunization does not induce infertility in mice.

    abstract:AIM:Placenta specific 1 (PLAC1) is a protein rarely expressed in normal cells, except it is important for placental development, with a possible role in the establishment of the mother-fetus interface. The gene is also highly active in a wide variety of cancers and therefore, immunization with PLAC1 peptides could poss...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0019

    authors: Liso A,Massenzio F,Stracci F

    更新日期:2017-05-01 00:00:00

  • Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

    abstract::Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.43

    authors: Shaffer DR,Rooney CM,Gottschalk S

    更新日期:2010-09-01 00:00:00

  • Designing effective vaccines for colorectal cancer.

    abstract::Achieving long-term control of colorectal cancers with therapeutic vaccines that generate potent anti-tumor T cell and antibody responses has been a goal for more than two decades. To date, clinical trials of these vaccines have demonstrated induction of immune responses, but clinical benefit has been limited. Improve...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.61

    authors: Patel SP,Osada T,Lyerly HK,Morse MA

    更新日期:2014-01-01 00:00:00

  • Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?

    abstract::Evaluation of: Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 171, 237-242 (2012). Clinical trials of a humanized anti-IL-6 receptor antibody, tocilizumab (TCZ), proved...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.47

    authors: Tanaka T

    更新日期:2013-07-01 00:00:00

  • Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity.

    abstract::Evaluation of: Rech AJ, Mick R, Martin S et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patents. Sci. Transl. Med. 4(134), 134ra62 (2012). Tregs are involved in the maintenance of immunological self-tolerance. Recent studies have revealed that Tregs ...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.12.116

    authors: Morita R,Hirohashi Y,Sato N

    更新日期:2012-11-01 00:00:00

  • Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia.

    abstract::Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0027

    authors: Okolo ON,Johnson AC,Yun S,Arnold SJ,Anwer F

    更新日期:2017-08-01 00:00:00

  • Reslizumab for pediatric eosinophilic esophagitis.

    abstract::Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.10.41

    authors: Walsh GM

    更新日期:2010-07-01 00:00:00